<DOC>
	<DOCNO>NCT00110045</DOCNO>
	<brief_summary>RATIONALE : Antifungals , caspofungin acetate , may effective treat fungal infection cause chemotherapy stem cell transplant . PURPOSE : This phase II trial study well caspofungin acetate work first-line treatment aspergillosis patient hematologic cancer patient undergone stem cell transplant .</brief_summary>
	<brief_title>Caspofungin Acetate Treating Aspergillosis Patients With Hematologic Cancer Patients Who Have Undergone Stem Cell Transplant</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine activity caspofungin acetate first-line therapy proven probable invasive aspergillosis , term response rate , patient hematologic malignancy patient undergone hematopoietic stem cell transplantation . Secondary - Determine 84-day response rate patient treat drug . - Determine 84-day survival rate patient treat drug . - Determine safety drug , term rate overall drug-related adverse event , rate overall drug-related serious adverse event , rate drug-related adverse event lead treatment discontinuation , patient . OUTLINE : This open-label , multicenter study . Patients stratify accord disease and/or type prior hematopoietic stem cell transplantation ( HSCT ) ( hematologic malignancy autologous HSCT v allogeneic HSCT ) . Patients receive caspofungin acetate IV approximately 1 hour daily day 1-15 absence disease progression unacceptable toxicity . Patients achieve complete response ( CR ) partial response ( PR ) day 15 may continue receive caspofungin acetate day 84 OR discontinue study treatment day 15 shift oral antifungal drug maintenance therapy prophylaxis , consider best interest patient . Patients achieve stable disease day 15 continue receive caspofungin acetate day 28 . These patient undergo second evaluation . Patients maintain stable disease continue receive caspofungin acetate day 84 . Patients achieve CR PR treat per CR PR treatment described . After completion study treatment , patient follow weekly 30 day . PROJECTED ACCRUAL : A total 149 patient ( 87 stratum 1 , 62 stratum 2 ) accrue study within 18 month .</detailed_description>
	<mesh_term>Aspergillosis</mesh_term>
	<mesh_term>Caspofungin</mesh_term>
	<mesh_term>Echinocandins</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis proven probable invasive aspergillosis ( IA ) Patients diagnosis possible IA eligible provide upgraded probable proven IA culture and/or histology result Aspergillus galactomannan evaluation within 7 day study entry Meets follow criterion : Diagnosis hematologic malignancy Underwent autologous allogeneic hematopoietic stem cell transplantation PATIENT CHARACTERISTICS : Age 18 Performance status Karnofsky 20100 % Life expectancy Not specify Hematopoietic Not specify Hepatic AST ALT ≤ 5 time upper limit normal ( ULN ) Bilirubin ≤ 5 time ULN Alkaline phosphatase ≤ 5 time ULN No severe hepatic insufficiency ChildPugh score ≤ 9 Renal No severe renal failure require hemodialysis peritoneal dialysis Creatinine &lt; 3.4 mg/dL Other Not pregnant nursing Negative pregnancy test Fertile patient must use effective doublemethod contraception No known HIV positivity No history allergy adverse reaction echinocandin drug No know bacterial infection adequately treat No psychological , familial , social , geographical condition would preclude study participation compliance PRIOR CONCURRENT THERAPY : Biologic therapy See Disease Characteristics Chemotherapy Not specify Endocrine therapy Not specify Radiotherapy Not specify Surgery Not specify Other Prior empirical antifungal therapy allow provide treatment duration ≤ 72 hour Prior prophylactic oral antifungal allow Prior prophylactic IV fluconazole allow More 14 day since prior concurrent investigational agent No prior participation study No prior echinocandins No concurrent antifungal therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2012</verification_date>
	<keyword>infection</keyword>
	<keyword>ataxia-telangiectasia</keyword>
	<keyword>accelerated phase chronic myelogenous leukemia</keyword>
	<keyword>acute undifferentiated leukemia</keyword>
	<keyword>blastic phase chronic myelogenous leukemia</keyword>
	<keyword>meningeal chronic myelogenous leukemia</keyword>
	<keyword>relapse chronic myelogenous leukemia</keyword>
	<keyword>chronic eosinophilic leukemia</keyword>
	<keyword>primary myelofibrosis</keyword>
	<keyword>chronic neutrophilic leukemia</keyword>
	<keyword>essential thrombocythemia</keyword>
	<keyword>polycythemia vera</keyword>
	<keyword>adult acute lymphoblastic leukemia remission</keyword>
	<keyword>recurrent adult acute lymphoblastic leukemia</keyword>
	<keyword>adult acute myeloid leukemia 11q23 ( MLL ) abnormality</keyword>
	<keyword>adult acute myeloid leukemia inv ( 16 ) ( p13 ; q22 )</keyword>
	<keyword>adult acute myeloid leukemia ( 15 ; 17 ) ( q22 ; q12 )</keyword>
	<keyword>adult acute myeloid leukemia ( 16 ; 16 ) ( p13 ; q22 )</keyword>
	<keyword>adult acute myeloid leukemia ( 8 ; 21 ) ( q22 ; q22 )</keyword>
	<keyword>adult acute myeloid leukemia remission</keyword>
	<keyword>recurrent adult T-cell leukemia/lymphoma</keyword>
	<keyword>stage I adult T-cell leukemia/lymphoma</keyword>
	<keyword>stage II adult T-cell leukemia/lymphoma</keyword>
	<keyword>stage III adult T-cell leukemia/lymphoma</keyword>
	<keyword>stage IV adult T-cell leukemia/lymphoma</keyword>
	<keyword>refractory chronic lymphocytic leukemia</keyword>
	<keyword>stage 0 chronic lymphocytic leukemia</keyword>
	<keyword>stage I chronic lymphocytic leukemia</keyword>
	<keyword>stage II chronic lymphocytic leukemia</keyword>
	<keyword>stage III chronic lymphocytic leukemia</keyword>
	<keyword>stage IV chronic lymphocytic leukemia</keyword>
	<keyword>progressive hairy cell leukemia , initial treatment</keyword>
	<keyword>refractory hairy cell leukemia</keyword>
	<keyword>prolymphocytic leukemia</keyword>
	<keyword>recurrent adult Hodgkin lymphoma</keyword>
	<keyword>stage I adult Hodgkin lymphoma</keyword>
	<keyword>stage II adult Hodgkin lymphoma</keyword>
	<keyword>stage III adult Hodgkin lymphoma</keyword>
	<keyword>stage IV adult Hodgkin lymphoma</keyword>
	<keyword>anaplastic large cell lymphoma</keyword>
	<keyword>angioimmunoblastic T-cell lymphoma</keyword>
	<keyword>recurrent mycosis fungoides/Sezary syndrome</keyword>
	<keyword>stage I mycosis fungoides/Sezary syndrome</keyword>
	<keyword>stage II mycosis fungoides/Sezary syndrome</keyword>
	<keyword>stage III mycosis fungoides/Sezary syndrome</keyword>
	<keyword>stage IV mycosis fungoides/Sezary syndrome</keyword>
	<keyword>recurrent cutaneous T-cell non-Hodgkin lymphoma</keyword>
	<keyword>stage I cutaneous T-cell non-Hodgkin lymphoma</keyword>
	<keyword>stage II cutaneous T-cell non-Hodgkin lymphoma</keyword>
	<keyword>stage III cutaneous T-cell non-Hodgkin lymphoma</keyword>
	<keyword>stage IV cutaneous T-cell non-Hodgkin lymphoma</keyword>
	<keyword>adult grade III lymphomatoid granulomatosis</keyword>
	<keyword>recurrent adult grade III lymphomatoid granulomatosis</keyword>
	<keyword>Waldenstrom macroglobulinemia</keyword>
	<keyword>extranodal marginal zone B-cell lymphoma mucosa-associated lymphoid tissue</keyword>
	<keyword>nodal marginal zone B-cell lymphoma</keyword>
	<keyword>recurrent adult Burkitt lymphoma</keyword>
	<keyword>recurrent adult diffuse large cell lymphoma</keyword>
	<keyword>recurrent adult diffuse mixed cell lymphoma</keyword>
	<keyword>recurrent adult diffuse small cleave cell lymphoma</keyword>
	<keyword>recurrent adult immunoblastic large cell lymphoma</keyword>
	<keyword>recurrent adult lymphoblastic lymphoma</keyword>
	<keyword>recurrent grade 3 follicular lymphoma</keyword>
	<keyword>recurrent mantle cell lymphoma</keyword>
	<keyword>recurrent grade 1 follicular lymphoma</keyword>
	<keyword>recurrent grade 2 follicular lymphoma</keyword>
	<keyword>recurrent marginal zone lymphoma</keyword>
	<keyword>recurrent small lymphocytic lymphoma</keyword>
	<keyword>contiguous stage II adult Burkitt lymphoma</keyword>
	<keyword>noncontiguous stage II adult Burkitt lymphoma</keyword>
	<keyword>stage I adult Burkitt lymphoma</keyword>
	<keyword>stage III adult Burkitt lymphoma</keyword>
	<keyword>stage IV adult Burkitt lymphoma</keyword>
	<keyword>contiguous stage II adult diffuse large cell lymphoma</keyword>
	<keyword>noncontiguous stage II adult diffuse large cell lymphoma</keyword>
	<keyword>stage I adult diffuse large cell lymphoma</keyword>
	<keyword>stage III adult diffuse large cell lymphoma</keyword>
	<keyword>stage IV adult diffuse large cell lymphoma</keyword>
	<keyword>contiguous stage II adult diffuse mixed cell lymphoma</keyword>
	<keyword>noncontiguous stage II adult diffuse mixed cell lymphoma</keyword>
	<keyword>stage I adult diffuse mixed cell lymphoma</keyword>
	<keyword>stage III adult diffuse mixed cell lymphoma</keyword>
	<keyword>stage IV adult diffuse mixed cell lymphoma</keyword>
	<keyword>contiguous stage II adult immunoblastic large cell lymphoma</keyword>
	<keyword>noncontiguous stage II adult immunoblastic large cell lymphoma</keyword>
	<keyword>stage I adult immunoblastic large cell lymphoma</keyword>
	<keyword>stage III adult immunoblastic large cell lymphoma</keyword>
	<keyword>stage IV adult immunoblastic large cell lymphoma</keyword>
	<keyword>contiguous stage II adult lymphoblastic lymphoma</keyword>
	<keyword>noncontiguous stage II adult lymphoblastic lymphoma</keyword>
	<keyword>stage I adult lymphoblastic lymphoma</keyword>
	<keyword>stage III adult lymphoblastic lymphoma</keyword>
	<keyword>stage IV adult lymphoblastic lymphoma</keyword>
	<keyword>contiguous stage II grade 1 follicular lymphoma</keyword>
	<keyword>noncontiguous stage II grade 1 follicular lymphoma</keyword>
	<keyword>stage I grade 1 follicular lymphoma</keyword>
	<keyword>stage III grade 1 follicular lymphoma</keyword>
	<keyword>stage IV grade 1 follicular lymphoma</keyword>
	<keyword>contiguous stage II grade 2 follicular lymphoma</keyword>
	<keyword>noncontiguous stage II grade 2 follicular lymphoma</keyword>
	<keyword>stage I grade 2 follicular lymphoma</keyword>
	<keyword>stage III grade 2 follicular lymphoma</keyword>
	<keyword>stage IV grade 2 follicular lymphoma</keyword>
	<keyword>contiguous stage II grade 3 follicular lymphoma</keyword>
	<keyword>noncontiguous stage II grade 3 follicular lymphoma</keyword>
	<keyword>stage I grade 3 follicular lymphoma</keyword>
	<keyword>stage III grade 3 follicular lymphoma</keyword>
	<keyword>stage IV grade 3 follicular lymphoma</keyword>
	<keyword>contiguous stage II mantle cell lymphoma</keyword>
	<keyword>noncontiguous stage II mantle cell lymphoma</keyword>
	<keyword>stage I mantle cell lymphoma</keyword>
	<keyword>stage III mantle cell lymphoma</keyword>
	<keyword>stage IV mantle cell lymphoma</keyword>
	<keyword>contiguous stage II marginal zone lymphoma</keyword>
	<keyword>noncontiguous stage II marginal zone lymphoma</keyword>
	<keyword>stage I marginal zone lymphoma</keyword>
	<keyword>stage III marginal zone lymphoma</keyword>
	<keyword>stage IV marginal zone lymphoma</keyword>
	<keyword>splenic marginal zone lymphoma</keyword>
	<keyword>contiguous stage II small lymphocytic lymphoma</keyword>
	<keyword>noncontiguous stage II small lymphocytic lymphoma</keyword>
	<keyword>stage I small lymphocytic lymphoma</keyword>
	<keyword>stage III small lymphocytic lymphoma</keyword>
	<keyword>stage IV small lymphocytic lymphoma</keyword>
	<keyword>intraocular lymphoma</keyword>
	<keyword>primary central nervous system non-Hodgkin lymphoma</keyword>
	<keyword>post-transplant lymphoproliferative disorder</keyword>
	<keyword>extramedullary plasmacytoma</keyword>
	<keyword>isolated plasmacytoma bone</keyword>
	<keyword>monoclonal gammopathy undetermined significance</keyword>
	<keyword>stage I multiple myeloma</keyword>
	<keyword>stage II multiple myeloma</keyword>
	<keyword>stage III multiple myeloma</keyword>
	<keyword>primary systemic amyloidosis</keyword>
	<keyword>refractory multiple myeloma</keyword>
	<keyword>de novo myelodysplastic syndrome</keyword>
	<keyword>myelodysplastic/myeloproliferative neoplasm , unclassifiable</keyword>
	<keyword>previously treat myelodysplastic syndrome</keyword>
	<keyword>secondary myelodysplastic syndrome</keyword>
	<keyword>atypical chronic myeloid leukemia , BCR-ABL1 negative</keyword>
	<keyword>chronic myelomonocytic leukemia</keyword>
	<keyword>disseminate neuroblastoma</keyword>
	<keyword>high risk metastatic gestational trophoblastic tumor</keyword>
	<keyword>recurrent neuroblastoma</keyword>
	<keyword>recurrent ovarian epithelial cancer</keyword>
	<keyword>stage II ovarian epithelial cancer</keyword>
	<keyword>stage III ovarian epithelial cancer</keyword>
	<keyword>stage IV ovarian epithelial cancer</keyword>
	<keyword>recurrent ovarian germ cell tumor</keyword>
	<keyword>recurrent malignant testicular germ cell tumor</keyword>
	<keyword>stage III malignant testicular germ cell tumor</keyword>
	<keyword>secondary acute myeloid leukemia</keyword>
	<keyword>stage IIIA breast cancer</keyword>
	<keyword>stage IIIB breast cancer</keyword>
	<keyword>stage IIIC breast cancer</keyword>
	<keyword>stage IV breast cancer</keyword>
	<keyword>chronic phase chronic myelogenous leukemia</keyword>
	<keyword>contiguous stage II adult diffuse small cleave cell lymphoma</keyword>
	<keyword>noncontiguous stage II adult diffuse small cleave cell lymphoma</keyword>
	<keyword>recurrent adult acute myeloid leukemia</keyword>
	<keyword>stage I adult diffuse small cleave cell lymphoma</keyword>
	<keyword>stage III adult diffuse small cleave cell lymphoma</keyword>
	<keyword>stage IV adult diffuse small cleave cell lymphoma</keyword>
	<keyword>T-cell large granular lymphocyte leukemia</keyword>
</DOC>